|
Synonyms
|
IL-1RP2, IL-1 epsilon, IL-1F9, IL-1H1
|
|
Species
|
Human
|
|
Accession
|
Q9NZH8
|
|
GeneID
|
56300
|
|
Source
|
重组体人Interleukin-36γ蛋白Escherichia coli.
|
|
Molecular Weight
|
Approximately 18.7 kDa, a single non-glycosylated polypeptide chain containing 169 amino acids.
|
|
Quantity
|
2µg/10µg/1000µg
|
|
AA Sequence
|
MRGTPGDADG GGRAVYQSMC KPITGTINDL NQQVWTLQGQ NLVAVPRSDS VTPVTVAVIT CKYPEALEQG RGDPIYLGIQ NPEMCLYCEK VGEQPTLQLK EQKIMDLYGQ PEPVKPFLFY RAKTGRTSTL ESVAFPDWFI ASSKRDQPII LTSELGKSYN TAFELNIND
|
|
Purity
|
> 95 % by SDS-PAGE and HPLC analyses.
|
|
Biological Activity
|
重组体人Interleukin-36γ蛋白Fully biologically active when compared to standard. The specific activity is determined by its binding ability in a functional ELISA. Immobilized rHuIL-36γ at 1 µg/mL can bind recombinant human IL-1 Rrp2 Fc Chimera with a range of 0.15-5 µg/mL.
|
|
Physical Appearance
|
Sterile Filtered White lyophilized (freeze-dried) powder.
|
|
Formulation
|
Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.
|
|
Endotoxin
|
Less than 1 EU/μg of rHuIL-36γ, 169a.a. as determined by LAL method.
|
|
Reconstitution
|
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
|
|
Storage
|
This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles.
|
|
重组体人Interleukin-36γ蛋白
|
|
|
Reference
|
1. Nicklin MJ, Barton JL, Nguyen M, et al. 2002. Genomics. 79:718-25.
2. Dinarello C, Arend W, Sims J, et al. 2010. Nat Immunol. 11:973.
3. Debets R, Timans JC, Homey B, et al. 2001. J Immunol. 167:1440-6.
4. Busfield SJ, Comrack CA, Yu G, et al. 2000. Genomics. 66:213-6.
5. Clark HF, Gurney AL, Abaya E, et al. 2003. Genome Res. 13:2265-70.
|
|
Background
|
重组体人Interleukin-36γ蛋白Interleukin-36 (IL-36) is a pro-inflammatory cytokine which plays an important role in the pathophysiology of several diseases. IL-36α, IL-36β, and IL-36γ (formerly IL-1F6, IL-1F8, and IL-1F9) are IL-1 family members that signal through the IL-1 receptor family members IL-1Rrp2 (IL-1RL2) and IL-1RAcP. IL-36γ is secreted when transfected into 293-T cells and it could constitute part of an independent signaling system analogous to interleukin-1 alpha (IL-1A), beta (IL-1B) receptor agonist and interleukin-1 receptor type I (IL-1R1). Furthermore, IL-36γ also can function as an agonist of NF-kappa B activation through the orphan IL-1-receptor-related protein 2. Recombinant human IL-36γ is synthesized as a 19 kDa, 169 amino acid (a.a.) protein that contains no signal sequence, no prosegment and no potential N-linked glycosylation site. Human to mouse, IL-36γ shares 53 % a.a. identity. Within the family, IL-36γ shares about 25 % ~ 55 % a.a. sequence identity with IL-1RA, IL-1β, IL-36RA, IL-36α, IL-37, IL-36β and IL-1F10.
|
